Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BeyondSpring’s Pivotal NSCLC Trial For Plinabulin Designed To Avoid Bavencio’s JAVELIN 200 Failure

Executive Summary

Lessons learned about blinding and stratification from Pfizer and Merck KGaA’s earlier Phase III disappointment shaped the design of BeyondSpring's ongoing Phase III trial of plinabulin in second- and third-line non-small cell lung cancer.

You may also be interested in...



BeyondSpring CEO On Plinabulin's Dual Regulatory Pathway For US and China

BeyondSpring’s lead clinical asset, plinabulin, is currently in late-stage global registrational studies for the prevention of chemotherapy-induced neutropenia and treatment of lung cancer, with read-outs expected soon.  CEO Lan Huang discussed coming catalysts and their potential with Scrip.

Pfizer/Merck KGAA's Bavencio Fails OS Endpoint In Second-Line Lung Cancer

The firms still hope to produce positive data in first-line non-small cell lung cancer in 2019, but Bavencio is falling well behind its checkpoint inhibitor competition.

Keeping Track: US FDA Clears On Target’s Cytalux, VBI’s PreHevbrio; Keytruda Grows In Adjuvant Melanoma

The latest FDA approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Topics

Related Companies

UsernamePublicRestriction

Register

PS140963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel